

Kansas Medicaid Supplemental Rebate Agreement Review Schedule

Supplemental rebate contracts for agents in drug classes on the PDL will be reviewed annually, according to the schedule below. Interested vendors should submit new or amended agreements by the 1st day of the review period. Bids for new products that become available in the interim should be received within 15 working days from the PDL review date. Additional information regarding the supplemental rebate bid submission process may be found at:

<http://www.khpa.ks.gov/pharmacy/download/BidSubmissionProcess.pdf>

Please note that the review of a supplemental rebate agreement does not imply a drug class review by the PDL Committee. Class reviews at the PDL Committee meetings will continue to occur only when there is a new agent in the class or when there is new, compelling, peer reviewed data about the class.

Review Period Begins	Contract Start Date	Drug Class	
January	April	H8B	Drugs for Insomnia - Non-scheduled Novel sleep agents
		J5D	Inhaled Beta 2 Agonists - Long Acting
		J5D	Inhaled Beta 2 Agonists - Short Acting
		C4J	DPP-4 Inhibitors
February	May	J7C, J7A	Cardiovascular Drugs - Beta-Blockers
		H2E	Drugs for Insomnia - Non-benzodiazepine sedative hypnotics
		M4D, M4J	Drugs to Lower Cholestrerol - HMG-CoA Reductase Inhibitors (Statins)
March	June	A9A	Cardiovascular Drugs - Calcium Channel Blockers (Dihydropyridines)
		A9A	Cardiovascular Drugs - Calcium Channel Blockers (Non-Dihydropyridines)
		N1B	Erythropoiesis - Stimulating Agents
April	July	P4L	Drugs for Osteoporosis - Bisphosphonates
		P5A	Drugs for Asthma - Inhaled Corticosteroids
		R1A, R1I	Urinary Incontinence Drugs - Anticholinergics
May	August	P1A	Growth Hormone
		H3F	Drugs for Migraines - Triptans
		C4G	Insulin (Delivery Systems)

Kansas Medicaid
Supplemental Rebate Agreement
Review Schedule

Review Period Begins	Contract Start Date	Drug Class	
June	September	C4L	Anti-Diabetic Drugs - Biguanides
		H6H	Drugs for Muscle Relaxation - Muscle Relaxants (Skeletal)
		H6H	Drugs for Muscle Relaxation - Muscle Relaxants (Spasticity)
July	October	C4N, C4R	Anti-Diabetic Drugs - Thiazolidinediones
		A4F, A4I	Cardiovascular Drugs - ARBs
		A4K	Cardiovascular Drugs - ACE Inhibitors/Calcium Channel Blocker Combos
August	November	Z2D	Drugs for Gastrointestinal Disorders - H2 Antagonists
		S2B, S2T, Q5E	Drugs for Inflammation/Pain - Non-Steroidal Anti-Inflammatory (NSAIDs)
		H6J	Antiemetic Drugs - Serotonin 5HT3 Antagonists
September	December	H4B	Antiherpes Virus Agents
		Z2Q	Drugs for Allergies - Non-Sedating Antihistamines
		Q7P	Drugs for Allergies - Intranasal Corticosteroids
October	January	H4B	Adjunct Antiepileptics
		Q6G	Glaucoma Drugs - Ophthalmic Prostaglandin Analogs
		M4E	Drugs for Hyperlipidemia - Fibrin Acid Derivatives
November	February	A4D	Cardiovascular Drugs - ACE Inhibitors
		C4K, C4S	Anti-Diabetic Drugs - 2nd Generation Sulfonylureas
		C4M	Anti-Diabetic Drugs - Alpha-glucosidase Inhibitors
December	March	C4K	Anti-Diabetic Drugs - Meglitinides
		C7A	Xanthine Oxidase Inhibitors
		D4J	Drugs for Gastrointestinal Disorders - Proton Pump Inhibitors